Wake Forest University

The Penn State Research Foundation

Virginia Tech Intellectual Properties, Inc.

The Pennsylvania State Research Foundation

Waldemar Debinski

Denise Gibo

Hetal Pandya

Denise Mazess Herpai

Jill Wykosky

Neil D Christensen

Poonam S Sonawane

Akiva Mintz

Carla Lema Tome

Jeffrey P Thompson

Sara Ferluga

Rafael V Davalos

Scott S Verbridge

Eduardo L Latouche

Glenn J Lesser

Denise M Gibo

Jill W Ivey

Carla Lema TomÉ

The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.

Molecular signature of cancer

Described herein are methods of electroporation that can include the steps of contacting a cell that is responsive to an EphA2 receptor ligand with an amount of an EphA2 receptor ligand and applying high-frequency irreversible electroporation to the cell. Also described herein are methods of treating cancer in a subject in need thereof, wherein the methods can include the steps of administering an amount of an EphA2 receptor ligand and applying high-frequency irreversible electroporation to a location on or within the subject.

Induced cell morphology electroporation

A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.

Multi-level specific targeting of cancer cells

Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising, in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13R&#x3b1;2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.

EPHA3 and multi-valent targeting of tumors

Provided herein are monoclonal antibodies that specifically bind IL-13RA2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers.

Antibodies against human and canine IL-13RA2

A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R&#x3b1;2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.

Nucleic acids encoding a fusion protein useful for multi-level specific targeting of cancer cells

Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13R&#x3b1;2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.

EPHA3 And multi-valent targeting of tumors

A targeting peptide that specifically binds to an IL13 receptor (e.g., wherein said targeting peptide is not an IL13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule. In some embodiments, the peptide specifically binds to the IL13R&#x3b1;2 protein.

IL-13 receptor binding peptides

Provided herein is an antibody (e.g., an isolated antibody) that specifically binds an epitope (e.g., linear epitope) within amino acids spanning the extracellular portion of human IL-13RA2. In some embodiments, the amino acids spanning the extracellular portion of human IL-13RA2 have at least 90% identity with the corresponding canine sequence of IL-13RA2. In some embodiments, the antibody specifically binds both human and canine IL-13RA2. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a recombinant antibody. In some embodiments, the antibody is humanized. In some embodiments, the antibody is the monoclonal antibody produced by hybridoma 1E10B9 or a recombinant form thereof.

Growing community of inventors

Winston-Salem, NC, United States of America

Waldemar Debinski